Clinical trials: Stage III Skin Cancer
Breast Cancer
Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer
RATIONALE: Gathering information about strength and range of motion over time from women undergoing surgery for breast cancer may help doctors learn more about recovery from surgery and on-going care.
- Trial name
- NCT00489125
- Testing
- physiologic testing
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- GIM4 (NCT01064635)
- Testing
- Letrozole
- Where
- Italy
- Volunteers
- 2,056 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Breast Cancer
S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897091
- Testing
- comparative genomic hybridization, microarray analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Estrogen Receptor-positive Breast Cancer
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
This study is designed to assess the safety and clinical activity of tamoxifen and the COX inhibitor, aspirin, given in combination with standard AC-T chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) for the treatment…
- Trial name
- Breast 51 (NCT04038489)
- Testing
- Aspirin, Tamoxifen Pill, Doxorubicin
- Where
- United States
- Sponsor
- University of Virginia
Early-stage Breast Cancer
Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients
Primarily, this clinical investigation compared the efficacy of tamoxifen + aminoglutethimide vs. tamoxifen alone in terms of prognosis (overall survival) in postmenopausal patients with potentially curative, operated hormone…
- Trial name
- NCT00309491
- Testing
- Tamoxifen alone, Tamoxifen + Aminoglutethimide
- Volunteers
- 2,021 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer, Cancer Survivor
Study of Support Groups for African-American Breast Cancer Survivors
RATIONALE: A study that evaluates successful Los Angeles-based, peer-led African American breast cancer survivor support groups may help in developing a guide on how to organize and maintain breast cancer support groups.
- Trial name
- NCT00949871
- Testing
- communication analysis, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- City of Hope Medical Center
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant…
- Trial name
- NCT01966471
- Testing
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab
- Where
- 295 sites in United States, Australia and 34 more
- Volunteers
- 1,846 people
- Sponsor
- Hoffmann-La Roche
Melanoma
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people…
- Trial name
- NCT05912244
- Testing
- IO102/IO103, Nivolumab-Relatlimab
- Where
- 9 sites in United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
This phase II trial compares the effect of dabrafenib and trametinib given continuously to given with a break in treatment (intermittent) in treating patients with stage III-IV melanoma that cannot be removed by surgery and…
- Conditions
- Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Trial name
- NCT02196181
- Testing
- Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate
- Where
- 752 sites in United States
- Volunteers
- 280 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Stage 0, Breast Cancer Stage I
Optimizing Surgical Decisions in Young Adults With Breast Cancer
The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer.
- Conditions
- Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- CONSYDER (NCT06275126)
- Testing
- CONSYDER decision aid
- Where
- 4 sites in United States
- Volunteers
- 800 people
- Sponsor
- Weill Medical College of Cornell University
Breast Cancer
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's…
- Trial name
- NCT00388726
- Testing
- E7389, Physician's Choice
- Where
- 137 sites in United States, Argentina and 15 more
- Volunteers
- 762 people
- Sponsor
- Eisai Inc.
Triple-Negative Breast Cancer
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.
- Trial name
- NCT04177108
- Testing
- Atezolizumab, Ipatasertib, Paclitaxel
- Where
- 182 sites in United States, Argentina and 35 more
- Volunteers
- 242 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
The purpose of this research study is to determine the safety of using the study drugs bevacizumab and ipilimumab together, and the doses in combination which can be given to people safely.
- Trial name
- NCT00790010
- Testing
- Bevacizumab Plus Ipilimumab Cohort 1, Bevacizumab Plus Ipilimumab Cohort 2, Bevacizumab Plus Ipilimumab Cohort 3
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
Early Stage Breast Cancer
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Primarily, this clinical investigation compared overall survival and recurrence-free survival in patients with hormone receptor-negative breast cancer treated with pre- and postoperative chemotherapy vs.
- Trial name
- NCT00309569
- Testing
- Cyclophosphamide, Methotrexate, Fluorouracil
- Volunteers
- 429 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive…
- Trial name
- NCT00354640
- Testing
- anastrozole, simvastatin, pharmacological study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT01160718
- Testing
- fulvestrant, selumetinib
- Where
- 17 sites in Belgium, Switzerland
- Volunteers
- 46 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107510
- Testing
- pegfilgrastim, carboplatin, docetaxel
- Where
- 120 sites in United States
- Volunteers
- 58 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
This phase II trial tests whether panitumumab and pembrolizumab in combination with standard of care chemotherapy before surgery (neoadjuvant) works to shrink tumors in patients with stage III-IV triple negative breast cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT05177796
- Testing
- Carboplatin, Cyclophosphamide, Doxorubicin
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- TEXT (NCT00066703)
- Testing
- exemestane, tamoxifen, triptorelin
- Where
- 228 sites in United States, Australia and 15 more
- Volunteers
- 2,672 people
- Sponsor
- ETOP IBCSG Partners Foundation